Health Authority Issues Warning Over Counterfeit Weight Loss Pens

The Health Products Regulatory Authority (HPRA) has issued a serious health warning concerning counterfeit tirzepatide injection pens that contain insulin. An investigation conducted by the HPRA in collaboration with Revenue’s Customs Service has uncovered these fraudulent products, which were sourced online and are believed to have originated outside of Europe. The counterfeit pens pose a significant health risk to users, particularly due to the potential for severe hypoglycaemia.

Laboratory tests revealed that two of the pens, marketed under the guise of tirzepatide, actually contained insulin, a hormone that regulates blood sugar levels. This misrepresentation can lead to dangerously low blood sugar levels, which can be life-threatening if not treated promptly. Tirzepatide is intended to assist individuals with type 2 diabetes and support weight loss, while the counterfeit products closely resemble the legitimate version branded as Mounjaro®.

Health Risks and Symptoms of Hypoglycaemia

The HPRA has advised anyone who suspects they may have used these counterfeit products to seek immediate medical assistance, especially if they are experiencing symptoms of hypoglycaemia. Symptoms include hunger, dizziness, sweating, shaking, heart palpitations, changes in vision, and confusion. More severe cases can lead to extreme drowsiness, seizures, and loss of consciousness, making swift treatment essential.

The potential dangers of these counterfeit pens highlight the risks associated with purchasing prescription medications from unregulated sources. The HPRA has previously reported detaining nearly 400,000 units of illegal medicines in the first half of 2025, emphasizing the ongoing issue of counterfeit drugs entering the market.

Public Awareness and Safety Measures

As of now, the HPRA confirmed that it has received no reports of harm linked to these specific counterfeit products, nor is there evidence that they have reached users. Nevertheless, the authority stresses the importance of vigilance when acquiring prescription medications. Consumers should be aware that products obtained from unregulated sources may be unsafe, ineffective, or completely fake, posing serious health risks.

The warning from the HPRA serves as a reminder of the critical need for public awareness regarding the dangers of counterfeit medications. Individuals are encouraged to consult healthcare professionals regarding any concerns about their medications and to ensure they are sourced from reputable, regulated outlets.